Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by 23andMe, Inc.

23andMe Regains Compliance With Nasdaq Listing Requirements
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe Appoints Three New Independent Directors to Board
From 23andMe, Inc.
Via GlobeNewswire
Tickers ANSS CDLX LSCC ME
23andMe Introduces New Feature Helping African Americans Trace Their Roots to Post Slavery Communities in the South
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe Announces Completion of 1-for-20 Reverse Stock Split
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe Announces 1-for-20 Reverse Stock Split
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe Announces Mathew Knowles as New Brand Ambassador
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe Launches New Genetic Report on Likelihood of Frequent Emotional Eating
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
Independent Directors of 23andMe Resign from Board
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe Reports First Quarter Fiscal 2025 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe Special Committee responds to CEO’s take-private proposal
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe Announces CEO’s Take-Private Proposal
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe to Report Q1 FY2025 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe Launches New Genetic Report on Bipolar Disorder
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME PTPI
23andMe to Report Q4 and Full Year FY2024 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe announces CEO’s intention to pursue a potential take-private
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.